Literature DB >> 16386200

Management of hypertension and diabetes: treatment goals, drug choices, current practice, and strategies for improving care.

Ann M Borzecki1, Dan R Berlowitz.   

Abstract

Diabetes and hypertension are common coexistent conditions, the combination of which results in an increased risk for cardiovascular and renal disease. Clinical trials have convincingly demonstrated the benefit of tight blood pressure control among patients with diabetes in reducing these risks. Furthermore, the choice of medication is less important than the level of control, especially in patients without renal involvement. Despite widespread dissemination of guidelines advocating tight control, many patients with diabetes continue to have uncontrolled blood pressure. The reasons for this are likely due to two main factors: blood pressure is more difficult to control in patients with diabetes, and providers are not treating these patients aggressively enough. Although the optimal approach to changing provider behavior and improving hypertension control is unknown, it likely involves a multi-faceted intervention that includes a disease management approach and targets multiple barriers to care, including those related to the providers, patients, and the health care organization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386200     DOI: 10.1007/s11906-005-0039-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  67 in total

Review 1.  Clinical inertia.

Authors:  L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

2.  Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

Authors:  S Andersen; L Tarnow; P Rossing; B V Hansen; H H Parving
Journal:  Kidney Int       Date:  2000-02       Impact factor: 10.612

3.  Treatment of hypertension in adults with diabetes.

Authors:  Carlos Arauz-Pacheco; Marian A Parrott; Philip Raskin
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

4.  Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers.

Authors:  Samy I McFarlane; Scott J Jacober; Nathaniel Winer; Jasjeet Kaur; Jonathan P Castro; MaryLou A Wui; Agnes Gliwa; Hans Von Gizycki; James R Sowers
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

5.  Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics.

Authors:  Murali K Duggirala; Robert M Cuddihy; Maria-Teresa Cuddihy; James M Naessens; Stephen S Cha; Jayawant N Mandrekar; Cynthia L Leibson
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Paul K Whelton; Joshua Barzilay; William C Cushman; Barry R Davis; Ekambaram Iiamathi; John B Kostis; Frans H H Leenen; Gail T Louis; Karen L Margolis; David E Mathis; Jamal Moloo; Chuke Nwachuku; Deborah Panebianco; David C Parish; Sara Pressel; Debra L Simmons; Udho Thadani
Journal:  Arch Intern Med       Date:  2005-06-27

10.  Risk factors for coronary heart disease mortality among persons with diabetes.

Authors:  F DeStefano; E S Ford; J Newman; J M Stevenson; S F Wetterhall; R F Anda; F Vinicor
Journal:  Ann Epidemiol       Date:  1993-01       Impact factor: 3.797

View more
  3 in total

1.  Patients' knowledge, attitudes, behaviour and health care experiences on the prevention, detection, management and control of hypertension in Colombia: a qualitative study.

Authors:  Helena Legido-Quigley; Paul Anthony Camacho Lopez; Dina Balabanova; Pablo Perel; Patricio Lopez-Jaramillo; Robby Nieuwlaat; J-D Schwalm; Tara McCready; Salim Yusuf; Martin McKee
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

2.  LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.

Authors:  John R Petrie; Steven P Marso; Stephen C Bain; Edward Franek; Stephan Jacob; Luis Masmiquel; Lawrence A Leiter; Martin Haluzik; Ilhan Satman; Mohamed Omar; Marina Shestakova; Luc Van Gaal; Johannes F Mann; Florian M M Baeres; Bernard Zinman; Neil R Poulter
Journal:  J Hypertens       Date:  2016-06       Impact factor: 4.844

3.  Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry.

Authors:  Jie Song; Chang-Sheng Sheng; Qi-Fang Huang; Li-Hua Li; Chang-Sheng Ma; Xiao-Hui Guo; Li-Nong Ji; Ji-Guang Wang
Journal:  J Hypertens       Date:  2016-08       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.